Incorrect password
evipedia.ai Suggest Edit

Enclomiphene to Improve Testosterone

Evidence Review created on 04/22/2026 using AI4L / Opus 4.7

Also known as: Enclomiphene Citrate, Androxal, trans-Clomiphene, Enclomifene

Motivation

Enclomiphene is the purified trans-isomer of clomiphene citrate, a long-used fertility drug. It belongs to a drug class called selective estrogen receptor modulators, compounds that block or activate estrogen signaling differently in different tissues. In men, it is used to raise testosterone by nudging the brain’s own hormonal signals upward rather than supplying testosterone from outside the body.

Interest has grown as an alternative to conventional testosterone replacement, which suppresses the body’s natural testosterone production and reduces fertility. Originally developed for regulatory approval as a male hypogonadism therapy, enclomiphene is now available in the United States only through compounding pharmacies after its sponsor halted the approval program. Online men’s-health clinics have brought it into wider use, while questions about long-term safety and cholesterol-pathway effects remain open.

This review examines the evidence for enclomiphene as a testosterone-raising intervention, the safety considerations around a pharmaceutical still outside formal approval, and how it compares to both direct testosterone replacement and its parent compound clomiphene.

Benefits - Risks - Protocol - Conclusion

This section lists high-quality, high-level overviews of enclomiphene and its use for testosterone restoration from expert sources.

No directly relevant, in-depth content discussing enclomiphene was found from Chris Kresser or Life Extension. Rhonda Patrick’s FoundMyFitness features a brief research summary on clomiphene/enclomiphene restoring testosterone while preserving fertility but not a substantive overview.

Grokipedia

Enclomifene

Comprehensive entry covering enclomiphene’s classification as the trans-isomer of clomiphene citrate, its mechanism as a selective estrogen receptor modulator, its pharmacological distinction from the zuclomiphene isomer, and its investigational use for male hypogonadism.

Examine

No dedicated article for enclomiphene was found on Examine.com. Examine.com does not typically cover prescription or investigational pharmaceutical compounds, focusing instead on over-the-counter dietary supplements.

ConsumerLab

No dedicated article for enclomiphene was found on ConsumerLab.com. ConsumerLab does not typically cover prescription medications.

Systematic Reviews

A selection of systematic reviews and meta-analyses evaluating enclomiphene and clomiphene for male hypogonadism and testosterone restoration.

No additional systematic reviews or meta-analyses specifically isolating enclomiphene’s effects (separate from racemic clomiphene) were found on PubMed as of 04/22/2026. The available meta-analyses pool clomiphene and enclomiphene data together due to the limited number of enclomiphene-only randomized controlled trials.

Mechanism of Action

Enclomiphene is a selective estrogen receptor modulator (SERM) — a class of drugs that binds estrogen receptors and blocks or activates them depending on tissue. Its testosterone-raising effect works through a targeted disruption of the feedback loop between the brain and the testes:

  • Estrogen receptor blockade in the hypothalamus: Enclomiphene occupies estrogen receptors (primarily ER-alpha — estrogen receptor alpha, the predominant estrogen receptor subtype in the hypothalamus) in the hypothalamus, preventing circulating estradiol from exerting its usual suppressive feedback. This disinhibition allows the hypothalamus to increase release of gonadotropin-releasing hormone (GnRH — the upstream signal that drives testosterone production)
  • Pituitary stimulation: Increased GnRH stimulates the anterior pituitary to release more luteinizing hormone (LH — the signal that tells the testes to make testosterone) and follicle-stimulating hormone (FSH — the signal that supports sperm production). Enclomiphene also antagonizes estrogen receptors on pituitary cells, further enhancing release of these hormones
  • Testicular testosterone production: Elevated LH stimulates Leydig cells in the testes to increase testosterone synthesis from cholesterol. Unlike external testosterone, this endogenous production maintains the very high intratesticular testosterone concentration (roughly 50–100 times serum levels) required for normal sperm production
  • Spermatogenesis preservation: Elevated FSH, combined with preserved intratesticular testosterone, continues to drive Sertoli-cell support for sperm production. This is the principal mechanistic advantage over exogenous testosterone, which suppresses both LH and FSH
  • Tissue-selective effects: As a SERM, enclomiphene acts as an estrogen antagonist in the hypothalamus and pituitary (the desired effect) but may retain partial agonist activity in other tissues such as bone, where estrogen signaling is important for maintaining bone mineral density. A Phase III trial in men (NCT01619683) found no adverse effects on bone mineral density
  • Desmosterol pathway inhibition: Enclomiphene inhibits sterol delta-24-reductase (DHCR24 — the enzyme that catalyzes the final step of converting desmosterol to cholesterol), leading to elevated desmosterol. The trans-isomer (enclomiphene) is roughly 10 times more potent than the cis-isomer (zuclomiphene) at this inhibition. The clinical significance at therapeutic doses is unresolved

Key pharmacological properties: enclomiphene is rapidly absorbed orally, with peak plasma concentrations 2–3 hours after ingestion and a half-life of roughly 10 hours. Tissue distribution follows its lipophilic profile — it circulates largely bound to plasma proteins and distributes into estrogen-receptor-expressing tissues (principally the hypothalamus and pituitary, with lesser reach into bone, liver, and reproductive tissues) without the prolonged accumulation seen with zuclomiphene. Metabolism is primarily hepatic via cytochrome P450 enzymes CYP3A4 and CYP2D6 (liver enzymes that metabolize many drugs). This contrasts sharply with zuclomiphene’s half-life of roughly 30 days, which underpins zuclomiphene’s tissue accumulation and prolonged estrogenic effects when racemic clomiphene is used.

Historical Context & Evolution

Enclomiphene’s development is intertwined with the longer history of clomiphene citrate:

  • 1956–1967: Clomiphene citrate was first synthesized at the Wm. S. Merrell Chemical Company and approved by the United States Food and Drug Administration (FDA) in 1967 as Clomid for female ovulatory dysfunction, becoming one of the most widely used fertility drugs worldwide
  • 1970s–1990s: Clinicians began using clomiphene off-label in men with low testosterone, recognizing its ability to raise testosterone through hypothalamic estrogen receptor blockade. This off-label use grew gradually despite the lack of a formal male indication
  • 2003–2015: Repros Therapeutics developed enclomiphene citrate (branded as Androxal) as a purified trans-isomer specifically for male secondary hypogonadism. Multiple Phase II and Phase III clinical trials were conducted, including studies demonstrating testosterone normalization, sperm preservation, and comparable efficacy to testosterone gel. An FDA New Drug Application was filed
  • 2015–2016: The FDA issued a Complete Response Letter for Androxal requesting additional clinical data. Concerns included cardiovascular safety data, reflecting the agency’s heightened scrutiny of testosterone-raising therapies following the 2015 FDA advisory on cardiovascular risks of testosterone products
  • 2021: The sponsor company discontinued the development program for enclomiphene for all indications, leaving no approved branded product on the path to market
  • 2022–present: Despite the end of branded development, enclomiphene has become widely available through compounding pharmacies. Men’s health clinics and telemedicine platforms began prescribing compounded enclomiphene as a fertility-preserving alternative to testosterone replacement therapy. The 2024–2025 publications of comparative retrospective studies and meta-analyses strengthened the evidence base even as regulatory approval remained out of reach

Expected Benefits

High 🟩 🟩 🟩

Testosterone Restoration to Normal Range

Multiple Phase II and Phase III clinical trials demonstrate that enclomiphene reliably increases serum total testosterone from below-normal into the normal range. A 2013 pharmacokinetic study by Wiehle and colleagues (44 men), sponsored by Repros Therapeutics — the company that developed enclomiphene as Androxal and therefore holds a direct financial interest in positive outcomes — found mean total testosterone reached roughly 604 ng/dL at the 25 mg dose after six weeks, up from baselines below 350 ng/dL. The 2025 meta-analysis by Hohl and colleagues of randomized controlled trials found selective estrogen receptor modulator therapy increased total testosterone by a mean difference of roughly 274 ng/dL versus placebo. Effects appear within two weeks and are stable with chronic dosing. The effect size in the target audience of men with confirmed secondary hypogonadism is large and consistent across trials.

Magnitude: Mean increase of roughly 200–275 ng/dL in total testosterone; normalization into the 500–700 ng/dL range from baselines below 350 ng/dL.

Preservation of Spermatogenesis & Fertility

Enclomiphene’s most clinically significant advantage over exogenous testosterone is preservation of sperm production. A Phase II trial by Wiehle and colleagues (2014; 73 men) directly compared enclomiphene to topical testosterone gel, finding enclomiphene maintained or increased sperm concentrations while testosterone gel caused marked reductions. A 2016 Phase III report by Kim and colleagues confirmed that enclomiphene preserved sperm counts in obese men with low testosterone, a population where topical testosterone strongly suppressed them. For health- and longevity-oriented men who wish to retain fertility, this is the defining reason to consider enclomiphene over standard testosterone replacement.

Magnitude: Sperm concentrations maintained or increased with enclomiphene versus roughly 40–90% suppression of sperm production with exogenous testosterone replacement.

Medium 🟩 🟩

Increased LH & FSH Levels

Enclomiphene consistently raises both LH and FSH, confirming that it drives the natural hormone cascade upward rather than suppressing it. The 2025 meta-analysis found significant increases in LH (mean difference of roughly 4.7 international units per liter) and FSH (mean difference of roughly 4.6 international units per liter) compared to placebo, in direct contrast to exogenous testosterone which suppresses both.

Magnitude: LH increase of roughly 4–5 international units per liter and FSH increase of roughly 4–5 international units per liter above baseline; both hormones are maintained well above the suppressed levels seen with exogenous testosterone.

Lower Estradiol Elevation Compared to Clomiphene

A 2024 retrospective study by Saffati and colleagues (66 men) found enclomiphene produced significantly lower estradiol changes than clomiphene (median change roughly -6 versus +18 picograms per milliliter, p = 0.001 — p-value is the probability that the observed difference arose by chance; values below 0.05 are generally considered statistically significant). This is clinically meaningful because elevated estradiol contributes to gynecomastia (male breast tissue enlargement), water retention, and mood disturbances.

Magnitude: Median estradiol change of roughly -6 picograms per milliliter with enclomiphene versus +18 picograms per milliliter with clomiphene (p = 0.001).

Fewer Adverse Events Than Clomiphene

The same 2024 Saffati study found statistically lower rates of decreased libido, reduced energy, and mood changes with enclomiphene than with clomiphene. Men on clomiphene reported any adverse event in roughly 18% of cases compared to about 3% with enclomiphene (odds ratio 0.18 — the ratio of the odds of an adverse event with enclomiphene to the odds with clomiphene, where values below 1 indicate lower odds; 95% confidence interval 0.07–0.44 — the range within which the true odds ratio is expected to fall with 95% certainty). This supports the mechanistic rationale for removing the zuclomiphene isomer, which contributes to many clomiphene-related side effects.

Magnitude: About 3% vs. 18% adverse event rate; odds ratio of roughly 0.18 for any adverse event with enclomiphene versus clomiphene.

Low 🟩

Bone Mineral Density Maintenance

A Phase III trial (NCT01619683; 300 men) specifically assessed enclomiphene’s effects on bone mineral density and found no adverse effects over the trial duration. By raising testosterone and by maintaining estrogenic signaling in bone (a characteristic of selective estrogen receptor modulators), enclomiphene may support bone health in men with low testosterone. Direct, long-term comparative fracture data are not available.

Magnitude: Not quantified in available studies.

Body Composition Improvement in Obese Men with Low Testosterone

Phase II work in obese men with acquired secondary hypogonadism (Kim and colleagues, 2016) showed that enclomiphene restored testosterone and preserved sperm counts; mechanistically, the restored testosterone is expected to support lean mass and reduce visceral fat when combined with diet and exercise, though dedicated body-composition endpoints are limited.

Magnitude: Not quantified in available studies.

Speculative 🟨

Cardiometabolic Benefits from Testosterone Normalization

Testosterone normalization in men with low baseline testosterone has been associated with improved insulin sensitivity, reduced visceral fat, and improved lipid profiles in broader literature. Enclomiphene, by restoring endogenous testosterone, may confer similar metabolic benefits, though no dedicated cardiometabolic outcome trials have been conducted with enclomiphene specifically. Evidence is mechanistic and extrapolated from the broader testosterone literature.

Long-Term Preservation of Testicular Function

By maintaining hypothalamic-pituitary-gonadal axis (the brain-testes signaling system) activity rather than suppressing it, enclomiphene may preserve Leydig cell function and testicular volume over the long term, in contrast to exogenous testosterone which can cause testicular atrophy. Evidence is mechanistic; direct long-term comparative data are lacking.

Cognitive or Mood Improvements Beyond Testosterone Effect

Some men report improvements in drive, mood, and cognitive clarity beyond what would be expected from the testosterone increase alone, potentially mediated by increased LH signaling or changes in neurosteroid synthesis. Current evidence is anecdotal and from small open-label cohorts.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variations in ESR1 (the gene coding for estrogen receptor alpha, the principal target of enclomiphene) may influence response. Polymorphisms in CYP3A4 and CYP2D6 (liver enzymes that metabolize enclomiphene) may affect plasma levels and clearance, though pharmacogenomic dosing guidelines have not been established. Variants affecting aromatase (CYP19A1, the enzyme that converts testosterone to estradiol) may modify how strongly feedback is triggered
  • Baseline biomarker levels: Men with secondary hypogonadism (low testosterone with low or inappropriately normal LH) are the ideal responders. Men with the lowest baseline testosterone and the highest baseline LH (approaching primary testicular failure) respond less robustly, as the drug depends on functional Leydig cells. Higher baseline estradiol means more negative feedback to antagonize and tends to predict a larger testosterone rise
  • Sex-based differences: Enclomiphene’s testosterone-boosting mechanism is specific to men. In women, clomiphene (including enclomiphene) stimulates ovulation rather than raising testosterone, and enclomiphene is not used in women for the goal of testosterone improvement
  • Pre-existing health conditions: Obesity is both a common cause of secondary hypogonadism and a modifier of response. Obese men have higher aromatase activity, which can partially counteract the testosterone response as extra testosterone is converted to estradiol. Men with primary testicular failure (Leydig cell damage from orchitis, chemotherapy, or genetic causes) will have limited or no response. Untreated sleep apnea and severe insulin resistance reduce response
  • Age-related considerations: Older men may have reduced Leydig cell reserve, potentially capping the maximal testosterone response. Men at the older end of the target range (over 60) have generally been underrepresented in enclomiphene trials; response tends to be smaller and thromboembolic considerations carry more weight. Younger men with obesity- or stress-driven secondary hypogonadism tend to be the strongest responders

Potential Risks & Side Effects

High 🟥 🟥 🟥

No high-evidence risks specific to enclomiphene have been established at clinical doses in current studies. Enclomiphene belongs to the selective estrogen receptor modulator class, which carries class-level concerns described below.

Medium 🟥 🟥

Thromboembolic Risk (Class Effect)

Selective estrogen receptor modulators as a class carry an increased risk of venous thromboembolism (blood clots in veins, which can include deep vein thrombosis and pulmonary embolism). In the Androxal clinical trial program, a small number of thromboembolic events were reported, most in men with additional risk factors. The absolute risk with enclomiphene appears low but is not precisely quantified due to limited sample sizes, and the class signal from older selective estrogen receptor modulator literature is well established.

Magnitude: Class-level increase in venous thromboembolism risk; absolute incidence with enclomiphene not precisely quantified, but appears low in trial data.

Desmosterol Elevation ⚠️ Conflicted

Enclomiphene inhibits sterol delta-24-reductase, the enzyme that converts desmosterol to cholesterol. The trans-isomer is roughly 10 times more potent than zuclomiphene at this inhibition. Peter Attia has publicly cited desmosterol elevation as a reason for reconsidering prescribing clomiphene-class drugs. Elevated desmosterol may alter cell membrane composition and has been associated in some work with atherogenic signaling, though the clinical significance at standard enclomiphene doses (12.5–25 milligrams) is unresolved. Legacy clomiphene prescribing information notes that serum sterols are not significantly altered at recommended doses, so the practical importance of the desmosterol finding is genuinely contested.

Magnitude: Measurable inhibition of sterol delta-24-reductase; clinical impact on cardiovascular risk at therapeutic doses not quantified in controlled studies.

Low 🟥

Headache

Headaches were reported in roughly 3% of participants in Phase II and Phase III Androxal clinical trials, typically mild and self-limited.

Magnitude: Roughly 3% incidence in clinical trials.

Hot Flashes

As an estrogen receptor antagonist, enclomiphene can produce hot flashes similar to those seen with other selective estrogen receptor modulators. The effect is generally mild and transient.

Magnitude: Not quantified in available studies.

Nausea & Mild Gastrointestinal Symptoms

Nausea and abdominal discomfort have been reported, particularly when taken on an empty stomach.

Magnitude: Not quantified in available studies.

Dizziness

Dizziness was reported in roughly 1% of participants in clinical trials.

Magnitude: Roughly 1% incidence in clinical trials.

Speculative 🟨

Visual Disturbances

Racemic clomiphene is associated with visual disturbances (blurred vision, floaters, light sensitivity) in a small percentage of users, attributed primarily to zuclomiphene accumulation. Whether purified enclomiphene carries the same risk is not definitively established, though the absence of zuclomiphene and enclomiphene’s shorter half-life suggest a substantially lower risk.

Long-Term Cardiovascular Effects

The FDA’s Complete Response Letter for Androxal requested additional cardiovascular safety data. While no cardiovascular signal was observed in the clinical trials, sample sizes and trial durations are too limited to rule out a small long-term risk. The TRAVERSE trial of exogenous testosterone, which found no excess cardiovascular risk from testosterone normalization, is indirectly reassuring but does not substitute for dedicated enclomiphene data.

Mood and Emotional Blunting

Some men report emotional blunting or reduced emotional range with selective estrogen receptor modulators, potentially due to central estrogen receptor antagonism. This effect was reported less often with enclomiphene than with clomiphene in comparative work, consistent with removal of the zuclomiphene isomer.

Hepatotoxicity

Enclomiphene is hepatically metabolized via CYP3A4 and CYP2D6. Idiosyncratic liver injury has been reported rarely with clomiphene; whether enclomiphene carries the same rare signal is not definitively established. Liver function monitoring is standard.

Risk-Modifying Factors

  • Genetic polymorphisms: Factor V Leiden (an inherited gene variant that makes blood more prone to clot) and other thrombophilia-associated (inherited or acquired conditions that predispose to abnormal blood clotting) mutations significantly increase the risk of thromboembolic events with selective estrogen receptor modulator use. CYP2D6 poor-metabolizer status may increase enclomiphene plasma levels and side-effect risk. Variants affecting CYP3A4 may likewise influence clearance
  • Baseline biomarker levels: Pre-existing elevated desmosterol or abnormal lipid profiles may amplify the relevance of enclomiphene’s effect on sterol synthesis. Elevated baseline hematocrit (red blood cell concentration) raises the likelihood of reaching a threshold requiring intervention when testosterone rises. Baseline coagulation status (prior elevated D-dimer, history of clotting events) increases thromboembolic risk
  • Sex-based differences: The male side-effect profile covered here does not transfer to women. Enclomiphene exposure during pregnancy carries significant teratogenic (capable of causing fetal harm) risk, consistent with the selective estrogen receptor modulator class
  • Pre-existing health conditions: A history of deep vein thrombosis, pulmonary embolism, or other thromboembolic events is a relative contraindication. Active liver disease may impair enclomiphene metabolism and increase drug exposure. Pre-existing visual symptoms warrant closer observation given the class association. Known hormone-sensitive cancers (for example prostate cancer) make testosterone elevation undesirable
  • Age-related considerations: Older men have inherently higher baseline thromboembolic risk, making the class effect more clinically relevant. Cardiovascular risk also increases with age, and the uncertain long-term cardiovascular data for enclomiphene justify extra caution in men over 60, particularly at the older end of the target range

Key Interactions & Contraindications

  • Prescription drug interactions:
    • CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may accelerate enclomiphene metabolism, reducing its efficacy — monitor clinical response and consider dose adjustment
    • CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, grapefruit juice) may raise enclomiphene plasma levels and increase side-effect risk — monitor or avoid combination
    • CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) may increase enclomiphene exposure — monitor for mood, visual, or vascular symptoms
    • Anticoagulants (warfarin, apixaban, rivaroxaban): potential additive bleeding and unclear thromboembolic interaction — closer monitoring of international normalized ratio (a measure of blood clotting time) and bleeding events is advisable
    • Exogenous testosterone (gels, injections, pellets): concurrent use is pharmacologically counterproductive — absolute contraindication in practice, as exogenous testosterone suppresses the same axis enclomiphene stimulates
    • Aromatase inhibitors (anastrozole, letrozole): sometimes used concurrently to blunt estradiol rise — use with caution, as combined blockade of estrogenic signaling can drive estradiol too low and affect bone, mood, and lipids
  • Over-the-counter medication interactions: No significant interactions with common over-the-counter medications have been established. Nonsteroidal anti-inflammatory drugs (NSAIDs — e.g., ibuprofen, naproxen) do not have known pharmacokinetic interactions, though their mild platelet effects should be considered alongside the class thromboembolic concern
  • Supplement interactions:
    • Anti-estrogenic supplements (diindolylmethane — a compound derived from cruciferous vegetables; calcium-D-glucarate) can have additive estrogen-lowering effects with enclomiphene — caution if estradiol is already trending low
    • Natural testosterone boosters (Tongkat ali, Eurycoma longifolia; Fadogia agrestis; zinc at high doses) may have additive effects on endogenous testosterone — monitor total testosterone, hematocrit, and estradiol if combining
    • High-dose vitamin E and fish oil have mild antiplatelet effects — consider in the context of the selective estrogen receptor modulator class thromboembolic signal
    • St. John’s wort is a CYP3A4 inducer — may reduce enclomiphene levels
  • Other intervention interactions: Weight-loss interventions (caloric deficit, GLP-1 receptor agonists such as semaglutide and tirzepatide — glucagon-like peptide-1 drugs) can themselves raise testosterone in obese men and may reduce the dose of enclomiphene required for a given response — monitor biomarkers so dosing is not excessive as weight comes down
  • Populations who should avoid enclomiphene:
    • Women who are pregnant or may become pregnant — absolute contraindication due to teratogenic risk
    • Men with primary hypogonadism (primary testicular failure, including Klinefelter syndrome — an XXY chromosomal condition) — enclomiphene requires functional Leydig cells; absolute contraindication for this indication
    • Individuals with a personal or strong family history of venous thromboembolism, known thrombophilia, or recent venous thromboembolism (<6 months) — absolute or relative contraindication based on severity
    • Active or severe liver disease (Child-Pugh Class B or C — a system for grading liver dysfunction) — relative to absolute contraindication based on severity
    • Men with active hormone-sensitive cancers (prostate, male breast cancer) — absolute contraindication
    • Known hypersensitivity to enclomiphene or clomiphene — absolute contraindication
    • Men with uncontrolled obstructive sleep apnea with very high baseline hematocrit (>52%) — defer until sleep apnea is treated or use extra caution with monitoring

Risk Mitigation Strategies

  • Confirm secondary hypogonadism before starting: Require two morning fasting total testosterone measurements below 300 nanograms per deciliter alongside low or inappropriately normal LH and FSH before initiating — prevents use in primary testicular failure where the drug will not work and the LH rise is clinically meaningless
  • Screen for thrombophilia in higher-risk men: Men with personal or family history of blood clots, stroke, or miscarriage should be screened for Factor V Leiden (an inherited gene variant that makes blood more prone to clot), prothrombin G20210A (an inherited gene variant that raises clotting-factor levels), and antiphospholipid markers before starting — reduces risk of thromboembolic events linked to the selective estrogen receptor modulator class
  • Start at a lower dose with slow titration: Begin at 12.5 milligrams daily or 25 milligrams three times weekly, and reassess clinical response and laboratory values at 4–6 weeks before any escalation to 25 milligrams daily — limits initial side-effect exposure and avoids overshooting testosterone
  • Baseline and ongoing bloodwork: Obtain baseline total and free testosterone, LH, FSH, sensitive estradiol, complete blood count with hematocrit, comprehensive metabolic panel, fasting lipid panel, and prostate-specific antigen if over 40; repeat at 6 weeks and 3–6 months thereafter — detects polycythemia (elevated red blood cell concentration), estradiol elevation, and lipid changes while they are still easy to correct
  • Monitor lipids and consider desmosterol testing: Obtain a fasting lipid panel at baseline and 12 weeks; where available, specialized desmosterol testing addresses the sterol-pathway concern directly — addresses desmosterol elevation risk flagged by clinicians including Peter Attia
  • Take with food: A meal reduces nausea and abdominal discomfort — mitigates mild gastrointestinal side effects
  • Report visual symptoms immediately: Any new blurred vision, floaters, or light sensitivity prompts discontinuation and ophthalmologic evaluation — addresses the residual class risk of visual disturbances
  • Use an accredited compounding pharmacy with third-party testing: Source from a Pharmacy Compounding Accreditation Board (PCAB)-accredited or state-licensed compounding pharmacy that provides a certificate of analysis with isomeric purity and potency data for each batch — addresses quality risk of compounded product with zuclomiphene contamination or incorrect potency
  • Periodic reassessment and structured discontinuation review: Reassess continued need at 6–12 months, considering whether weight loss, sleep, and stress interventions have addressed the underlying cause of low testosterone — reduces exposure to long-term risks whose magnitude is not yet fully defined

Therapeutic Protocol

The protocol below synthesizes the Phase II and Phase III Androxal trial program and current clinical practice at men’s health clinics. It presents the mainstream dosing approach and its common variations without framing any single approach as the default.

  • Standard dose (mainstream approach): 12.5–25 milligrams orally once daily. Clinical trials evaluated 6.25, 12.5, and 25 milligram doses, with 12.5 and 25 milligrams producing the most consistent testosterone responses. A 2014 pharmacodynamic study found a dose-dependent rise in free testosterone up to 12.5 milligrams, with 25 milligrams reaching a non-dose-dependent steady state
  • Alternative protocols (competing practitioner approaches):
    • Every-other-day dosing of 25 milligrams — used by some men’s-health clinicians (including Dr. Kyle Gillett and practitioners affiliated with Marek Health) to reduce total weekly drug exposure while maintaining testosterone in range
    • Three-to-five-days-a-week dosing (e.g., Monday–Friday) — another common clinic protocol; the 10-hour half-life allows effective coverage while leaving weekend washout
    • Cycled use (e.g., 3 months on, 1 month off) — used by practitioners favoring intermittent exposure; not supported by superior efficacy data
  • Best time of day: Enclomiphene can be taken at any consistent time. Morning dosing is most common and aligns with the natural diurnal testosterone peak. Consistency matters more than the specific clock time
  • Half-life: Roughly 10 hours, with peak plasma concentrations at 2–3 hours. Despite the short plasma half-life, downstream effects on LH and testosterone persist for roughly one week after stopping the drug, reflecting the timescale of the pituitary-testicular axis
  • Single vs. split doses: Single daily dosing was used in all clinical trials and is standard. There is no evidence that split dosing adds benefit, and it tends to reduce adherence
  • Genetic polymorphisms: No formal pharmacogenomic dosing guidelines exist for enclomiphene. CYP3A4 and CYP2D6 poor-metabolizer status may lead to higher exposure and argue for the lower end of the dose range in men with unusual sensitivity or side effects
  • Sex-based differences: The testosterone-boosting protocol is specific to men. In women, clomiphene/enclomiphene is used for ovulation induction at different doses and on different schedules; this is not within the scope of the current topic
  • Age-related considerations: No formal age-specific dose adjustments exist. Younger men (under 40) with documented secondary hypogonadism are often considered the strongest candidates because fertility preservation is a high priority and thromboembolic risk is lowest. Men over 60 should be started at the lower end of the dose range (12.5 milligrams) with closer monitoring for thromboembolic events and hematocrit rises
  • Baseline biomarker levels: Total testosterone below 300 nanograms per deciliter on two morning fasting measurements with low or inappropriately normal LH identifies appropriate candidates. Elevated baseline hematocrit (>50%) or estradiol (>50 picograms per milliliter on a sensitive assay) warrants a more cautious starting dose and closer monitoring
  • Pre-existing health conditions: Obese men with aromatase-driven secondary hypogonadism may require the upper end of the dose range and often benefit from concurrent weight loss, which further raises testosterone and reduces required drug doses. Men with uncontrolled sleep apnea should have the sleep apnea addressed first, as testosterone rises on top of uncontrolled sleep apnea can push hematocrit higher

Discontinuation & Cycling

  • Lifelong versus short-term use: Enclomiphene can be used as a short-term bridge (e.g., while weight loss, sleep optimization, or stress reduction addresses the underlying cause of low testosterone) or as long-term therapy for men with persistent secondary hypogonadism. There is no consensus that either approach is superior
  • Withdrawal effects: No formal withdrawal syndrome has been documented. Testosterone returns to pre-treatment levels within roughly 2–4 weeks of stopping, as the downstream effect on LH and testosterone wanes over about one week. The symptomatic “dip” some men experience on stopping is the return of underlying low testosterone, not a distinct withdrawal effect
  • Tapering: No formal taper is required. Some clinicians prefer a gradual reduction (e.g., moving from daily to every-other-day for 2–4 weeks) to allow a smoother hormonal transition, but evidence of rebound is lacking
  • Cycling: Some practitioners recommend cycling (e.g., 5 days on, 2 days off, or 3 weeks on, 1 week off) on the theory of preventing receptor desensitization and allowing periodic assessment of underlying endogenous hormone function. Phase II and Phase III trials used continuous daily dosing for up to 16 weeks without evidence of tolerance, so cycling is based on clinical preference and is not clearly required to maintain efficacy

Sourcing and Quality

  • Regulatory status: Enclomiphene is not FDA-approved for any indication in the United States. The branded product Androxal was discontinued in 2021. All United States enclomiphene is produced by compounding pharmacies; in other jurisdictions availability varies
  • Compounding pharmacy accreditation: Seek pharmacies that are Pharmacy Compounding Accreditation Board (PCAB)-accredited, compliant with United States Pharmacopeia (USP) chapters 795 (nonsterile compounding) and 797 (sterile compounding) as applicable, and that provide a certificate of analysis with identity, potency, and purity testing for each batch
  • Isomeric purity: Since enclomiphene is the trans-isomer of clomiphene, production quality must ensure minimal contamination with the zuclomiphene (cis) isomer. High-quality compounders verify isomeric purity by chiral high-performance liquid chromatography (a laboratory technique for separating and quantifying related compounds)
  • Reputable sources: Well-regarded compounding pharmacies offering enclomiphene in the United States include Empower Pharmacy, Strive Pharmacy, and Olympia Pharmacy, typically accessed through urologists, endocrinologists, or telemedicine men’s-health platforms such as Marek Health
  • Storage: Capsules should be stored at controlled room temperature (roughly 20–25 degrees Celsius, or 68–77 degrees Fahrenheit), protected from moisture and direct light, and kept in original containers

Practical Considerations

  • Time to effect: Testosterone begins rising within about 2 weeks, with steady state typically reached by 4–6 weeks. Symptomatic benefits (energy, libido, mood, body composition) generally follow on an 8–12 week timeline, consistent with the time course of testosterone-mediated physiological change
  • Common pitfalls:
    • Using enclomiphene for primary hypogonadism where LH is already elevated — the drug will push LH higher without raising testosterone and may create false reassurance
    • Expecting same-week symptomatic results — enclomiphene works through the endogenous hormone cascade and needs weeks to manifest clinically
    • Combining with exogenous testosterone — pharmacologically counterproductive and common among men transitioning between protocols without a clean washout
    • Confusing enclomiphene with clomiphene (Clomid) — they share mechanism but differ in side-effect profile due to zuclomiphene content
    • Sourcing from unverified compounding pharmacies — quality varies, and zuclomiphene contamination reintroduces the side-effect burden enclomiphene is designed to avoid
    • Over-reliance on the drug while neglecting sleep, weight, and stress — these upstream factors often drive secondary hypogonadism and limit the drug’s response if unaddressed
  • Regulatory status: Enclomiphene is not FDA-approved and is available only as a compounded medication requiring a prescription. Off-label use of racemic clomiphene (Clomid), which is FDA-approved for female ovulatory dysfunction, is a related but distinct option used by some clinicians
  • Cost and accessibility: Compounded enclomiphene typically costs roughly 30–100 United States dollars per month depending on pharmacy, dose, and prescribing channel. It requires a prescription, usually obtained through urology, endocrinology, or telemedicine men’s-health platforms. Insurance generally does not cover compounded enclomiphene, while FDA-approved testosterone products are more commonly reimbursed — insurers therefore face a structural incentive to favor the FDA-approved comparator over compounded enclomiphene, which in turn influences guideline formation and research funding priorities in ways that are relevant when interpreting comparative evidence

Interaction with Foundational Habits

  • Sleep: Direct interaction. Poor sleep and untreated obstructive sleep apnea are leading upstream drivers of secondary hypogonadism; short sleep (for example restricting to 5 hours per night for one week) can reduce testosterone by roughly 10–15%. Enclomiphene does not itself disrupt sleep architecture, but its response is blunted when baseline sleep is poor. Addressing sleep apnea and extending sleep to 7–9 hours supports the same axis enclomiphene stimulates and often reduces the required dose
  • Nutrition: Direct interaction. Enclomiphene can be taken with or without food, though food reduces nausea. A diet with adequate zinc (involved in testosterone synthesis), vitamin D (supports brain-testes axis function), magnesium, and healthy fats (cholesterol is the substrate for steroidogenesis — the biosynthesis of steroid hormones) supports the testosterone-producing pathway enclomiphene engages. Caloric excess and high body fat increase aromatase activity (which converts testosterone to estradiol) and partially counteract enclomiphene’s effects; a moderate caloric deficit in overweight men augments the testosterone response
  • Exercise: Potentiating interaction. Resistance training and zone 2 cardiovascular exercise (sustained moderate-intensity aerobic work below the lactate threshold) each support testosterone and improve insulin sensitivity (insulin resistance contributes to secondary hypogonadism). High-intensity interval training (HIIT — short bursts of near-maximal effort alternated with recovery) acutely raises testosterone. There are no timing constraints relative to enclomiphene dosing. Overtraining and chronic energy deficiency, however, can suppress the brain-testes axis and blunt enclomiphene’s effect
  • Stress management: Indirect interaction. Chronic psychological stress elevates cortisol, which suppresses GnRH and contributes to secondary hypogonadism. Enclomiphene works downstream of GnRH by blocking estrogen feedback, but severe stress-driven suppression of GnRH release can limit its efficacy. Stress reduction practices (meditation, adequate recovery, strong social connection) support the hormonal environment enclomiphene is designed to optimize

Monitoring Protocol & Defining Success

Baseline assessment is performed before starting enclomiphene to confirm secondary hypogonadism, rule out contraindications, and establish comparison values. It includes two morning fasting total testosterone measurements, LH, FSH, sensitive estradiol, complete blood count with hematocrit, comprehensive metabolic panel including liver enzymes, fasting lipid panel, prostate-specific antigen for men over 40, and a semen analysis if fertility is a goal.

Ongoing monitoring cadence: at 4–6 weeks after starting, again at 12 weeks, then every 6 months while on therapy. Additional checks are triggered by dose changes, symptom changes, or borderline baseline values.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Total Testosterone 500–900 ng/dL Primary efficacy marker Conventional reference: 264–916 ng/dL. Morning fasting sample; measure at 4–6 weeks, 12 weeks, then every 6 months
Free Testosterone 10–25 pg/mL (direct) or 2–3% of total Bioavailable testosterone fraction Equilibrium dialysis is the gold standard; calculated free testosterone is acceptable. Measure with total testosterone
LH 3–10 IU/L Confirms mechanism — LH should rise, not fall Luteinizing hormone — the pituitary signal that tells the testes to make testosterone. Conventional reference: 1.7–8.6 IU/L. LH rising >15 IU/L without adequate testosterone response suggests primary testicular failure
FSH 2–10 IU/L Confirms gonadotropin stimulation and fertility preservation Follicle-stimulating hormone — the pituitary signal that supports sperm production. Conventional reference: 1.5–12.4 IU/L. Should rise or remain in range
Sensitive Estradiol 20–35 pg/mL Monitors estrogen status; should not rise excessively Conventional reference: 8–35 pg/mL. Use sensitive LC-MS (liquid chromatography-mass spectrometry) assay in men. Large rises may require dose reduction or aromatase inhibitor
Hematocrit 40–50% Screens for polycythemia (elevated red blood cell concentration) from testosterone rise Conventional reference: 38.3–48.6%. Values >54% require intervention. Risk is lower than with exogenous testosterone
ALT / AST ALT 10–26 U/L, AST 10–26 U/L (men) Safety monitoring for liver function Alanine / aspartate aminotransferase — liver enzymes. Conventional reference: ALT 7–56 U/L, AST 10–40 U/L. Baseline, 12 weeks, then annually. Enclomiphene is hepatically metabolized
Fasting Lipid Panel LDL <100 mg/dL; HDL >40 mg/dL; TG <100 mg/dL Monitors for desmosterol-pathway lipid effects LDL = low-density lipoprotein; HDL = high-density lipoprotein; TG = triglycerides. Fasting required. Baseline and 12 weeks. Consider specialized desmosterol testing if available
PSA <1.5 ng/mL (men 40–49); age-adjusted thereafter Screens for testosterone-stimulated prostate changes Prostate-specific antigen. Men 40 and over only. Baseline and annually. Conventional reference varies by age
Semen Analysis >15 million sperm/mL Confirms fertility preservation Baseline and at 3–6 months if fertility is a stated goal

Qualitative markers to monitor:

  • Energy levels and fatigue (expected to improve within 4–8 weeks)
  • Libido and sexual function (typically improves within 4–12 weeks)
  • Mood, motivation, and cognitive clarity
  • Body composition (gradual; assess over 3–6 months)
  • Exercise performance and recovery
  • Any new visual disturbances, headaches, or leg pain or swelling

Emerging Research

  • Comparative safety data for enclomiphene versus clomiphene: The retrospective cohort by Saffati et al. (2024, 66 men) established preliminary comparative evidence that enclomiphene has lower estradiol elevation and fewer adverse events than clomiphene, prompting calls for larger prospective studies
  • Most comprehensive meta-analytic synthesis to date: The 2025 systematic review by Hohl et al. represents the most rigorous synthesis of randomized controlled trial data, establishing selective estrogen receptor modulator therapy as non-inferior to testosterone gel for total testosterone while preserving gonadotropin levels
  • Fertility preservation innovations: A 2025 review by Hochu and colleagues positioned enclomiphene alongside intranasal testosterone, oral testosterone undecanoate (a form of testosterone absorbed through the lymphatic system), and hCG co-administration as part of an evolving landscape of fertility-preserving testosterone therapies
  • Musculoskeletal adjunct trial: An ongoing Phase II trial (NCT04944836; roughly 58 participants; recruiting) is studying clomiphene citrate as sex-hormone supplementation to improve rotator cuff repair outcomes in hypogonadal men, exploring musculoskeletal applications of selective estrogen receptor modulator-mediated testosterone elevation
  • Desmosterol clinical significance: Research continues into whether enclomiphene’s inhibition of sterol delta-24-reductase and the resulting desmosterol elevation has meaningful cardiovascular or cellular consequences at therapeutic doses. This remains the single most consequential unresolved question and could strengthen or weaken the long-term case for enclomiphene depending on outcome
  • Cardiovascular outcomes evidence: Indirect reassurance from the TRAVERSE trial of exogenous testosterone (Lincoff et al., 2023) does not substitute for dedicated cardiovascular outcome data on enclomiphene; registry-based cohort analyses of compounded enclomiphene users are beginning to emerge from academic urology centers and will shape long-term risk estimates
  • Compounding standardization initiatives: With enclomiphene’s growing popularity through compounding pharmacies, professional organizations and state boards are focusing on quality standards including verified isomeric purity — an area likely to tighten over the next few years

Conclusion

Enclomiphene raises testosterone in men with secondary hypogonadism by relieving estrogen feedback on the brain rather than supplying hormone from outside the body. The clinical evidence supports reliable testosterone normalization and preservation of sperm production — the defining advantage over standard testosterone replacement for men who value fertility. Compared with its parent compound clomiphene, the evidence points to lower estradiol elevation and a milder side-effect profile.

The limitations are real. Enclomiphene is not approved for sale in the United States and its branded development was halted, leaving compounding pharmacies as the only domestic source. Long-term safety data are limited. The desmosterol elevation finding, the blood-clot risk inherent to the drug class, and the absence of dedicated heart-outcome trials all remain open questions. The evidence base still leans on a small number of trials sponsored by Repros Therapeutics — the company that developed the branded product — supplemented by retrospective work. Insurers typically reimburse approved testosterone products but not compounded enclomiphene, a structural incentive favoring the approved comparator in guideline formation and research funding.

For the health- and longevity-oriented audience, the available evidence most directly applies to men with confirmed secondary hypogonadism who value fertility preservation and endogenous hormone production, and who are positioned to pursue accredited compounding, structured monitoring, and foundational habit support alongside the drug. In older men and those with clotting or heart-risk factors, the evidence base is thinner and the class-level signals more prominent, and the trial record does not converge on a single universally correct protocol.

Top - Benefits - Risks - Protocol